icotinib hydrochloride
The hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Icotinib selectively inhibits the wild-type and several mutated forms of EGFR tyrosine kinase. This may lead to an inhibition of EGFR-mediated signal transduction and may inhibit cancer cell proliferation. EGFR, a receptor tyrosine kinase, has been upregulated in a variety of cancer cell types.
| Synonym: | icotinib HCl |
|---|---|
| Foreign brand name: | Conmana |
| Code name: | BPI-2009 BPI-2009H |
| Chemical structure: | (1,4,7,10)tetraoxacyclododecino(2,3-g)quinazolin-4-amine, N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-, hydrochloride (1:1) |